Moderna Inc. buy Traumtanz
Start price
05.04.20
/
50%
€33.80
Target price
09.04.20
€40.00
Performance (%)
-12.68%
End price
09.04.20
€29.52
Summary
This prediction ended on 09.04.20 with a price of €29.52. The price of Moderna Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -12.68%. Traumtanz has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Moderna Inc. | -9.865% | -9.865% | -29.367% | -78.505% |
iShares Core DAX® | 1.056% | 1.056% | 18.108% | 16.006% |
iShares Nasdaq 100 | -1.886% | -0.160% | 26.970% | 36.233% |
iShares Nikkei 225® | 2.553% | 4.359% | 17.676% | 10.955% |
iShares S&P 500 | -0.434% | 0.224% | 24.986% | 37.667% |
According to Traumtanz what are the pros and cons of Moderna Inc. for the foreseeable future?
Pros
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio
Growths faster than the competition
Sustainability is important
Stable Large shareholder and/or long term investor
Medium risks for its business
Top 10 in its market
Small cyclical dependencies
Known brand
Future proof or reliable business model
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
High dividend yield expected
positive Cash Flow expected
Good rating
Standard Investments for future growth
Valuable balance sheet
ROE higher than 10% per year
Cons
Comments by Traumtanz for this prediction
In the thread Moderna Inc. diskutieren
Buy mit Kursziel 40,0
ein vielversprechender Chart einer jungen Aktie:
https://en.wikipedia.org/wiki/Moderna
...In January 2020, Moderna announced development of a vaccine to inhibit COVID-19 coronavirus, in competition with other biotechnology companies, such as Gilead Sciences, Vaxart, Inovio Pharmaceuticals, and Novavax. In March 2020, the Phase I human study of the vaccine candidate began in partnership with the US National Institute of Allergy and Infectious Diseases.
https://en.wikipedia.org/wiki/Moderna
...In January 2020, Moderna announced development of a vaccine to inhibit COVID-19 coronavirus, in competition with other biotechnology companies, such as Gilead Sciences, Vaxart, Inovio Pharmaceuticals, and Novavax. In March 2020, the Phase I human study of the vaccine candidate began in partnership with the US National Institute of Allergy and Infectious Diseases.
https://www.onvista.de/aktien/MODERNA-INC-Aktie-US60770K1079
aber Vorsicht mit der Euphorie von diesen Kriegsgewinnlern...man weiss noch nicht, wer sich hier durchsetzten wird....wenn überhaupt!
aber Vorsicht mit der Euphorie von diesen Kriegsgewinnlern...man weiss noch nicht, wer sich hier durchsetzten wird....wenn überhaupt!
In the thread Trading Moderna Inc.
Buy beendet
Stopped prediction by Traumtanz for Moderna Inc.
Moderna Inc.
Start price
Target price
Perf. (%)
€73.21
02.12.23
02.12.23
€74.00
02.12.24
02.12.24
15.01%
14.12.23
14.12.23
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio
Moderna Inc.
Start price
Target price
Perf. (%)
€71.59
24.11.23
24.11.23
€70.00
24.11.24
24.11.24
2.26%
02.12.23
02.12.23
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio
Moderna Inc.
Start price
Target price
Perf. (%)
€70.95
23.11.23
23.11.23
€74.00
23.11.24
23.11.24
0.90%
24.11.23
24.11.23
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio
Moderna Inc.
Start price
Target price
Perf. (%)
€70.63
21.11.23
21.11.23
€74.00
21.11.24
21.11.24
0.45%
23.11.23
23.11.23
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio
Moderna Inc.
Start price
Target price
Perf. (%)
€72.57
20.11.23
20.11.23
€74.00
20.11.24
20.11.24
-2.67%
21.11.23
21.11.23
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio
Moderna Inc.
Start price
Target price
Perf. (%)
€69.64
31.10.23
31.10.23
€71.00
31.10.24
31.10.24
4.21%
20.11.23
20.11.23
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio
Moderna Inc.
Start price
Target price
Perf. (%)
€183.12
18.01.23
18.01.23
€110.00
18.01.24
18.01.24
-61.97%
31.10.23
31.10.23
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio
Moderna Inc.
Start price
Target price
Perf. (%)
€172.00
10.01.23
10.01.23
€180.00
10.01.24
10.01.24
6.47%
18.01.23
18.01.23
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio
Moderna Inc.
Start price
Target price
Perf. (%)
€164.38
14.11.22
14.11.22
€175.00
14.11.23
14.11.23
9.00%
16.11.22
16.11.22
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio
Moderna Inc.
Start price
Target price
Perf. (%)
€127.18
05.12.20
05.12.20
€130.00
2.20%
07.12.20
07.12.20
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio
Moderna Inc.
Start price
Target price
Perf. (%)
€93.50
26.11.20
26.11.20
€100.00
12.81%
27.11.20
27.11.20
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio
Moderna Inc.
Start price
Target price
Perf. (%)
€54.99
03.06.20
03.06.20
€60.00
04.06.20
04.06.20
-4.40%
04.06.20
04.06.20
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio
Moderna Inc.
Start price
Target price
Perf. (%)
€58.34
15.05.20
15.05.20
€85.00
27.05.20
27.05.20
-4.61%
27.05.20
27.05.20
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio
Moderna Inc.
Start price
Target price
Perf. (%)
€44.00
03.05.20
03.05.20
€70.00
14.05.20
14.05.20
33.00%
14.05.20
14.05.20
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio
Moderna Inc.
Start price
Target price
Perf. (%)
€37.43
16.04.20
16.04.20
€50.00
21.04.20
21.04.20
32.71%
21.04.20
21.04.20
Normal challenges to pay loans and raise capital
Innovative
Some uniques
Differentiated customer and product portfolio